
    
      This is a single-center, open label, active controlled, dose-escalation, parallel group study
      to assess the safety, tolerability and immunogenicity of NBP608 in healthy adult volunteers.
      Total of 150 healthy subjects aged 20 and over are enrolled, and each subject is administered
      with single dose of vaccine which is sequentially assigned to active group 1, 2 and study
      group 1~3 in 1:1:1:1:1 ratio(30 subjects are enrolled at each groups) .
    
  